Breast cancer metastatic mouse models are experimental approaches in which mice are genetically manipulated to develop a mammary tumor leading to distant focal lesions of mammary epithelium created by metastasis. Mammary cancers in mice can be caused by genetic mutations that have been identified in human cancer. This means models can be generated based upon molecular lesions consistent with the human disease.

Breast cancer metastasis

Metastasis is a process of migration of tumour cells from the primary cancer site to a distant location where the cancer cells form secondary tumors. Metastatic breast cancer represents the most devastating attribute of cancer and it is considered an advanced-stage event.[1] Human breast cancer metastasizes to multiple distant organs such as the brain, lungs, bones and liver.

Genetic diversity between primary and metastatic tumor

The classical theory developed in the early 70's anticipated that metastasis is due to genetically determined subpopulations in primary tumours.[2] The genetic variance between metastatic foci is significant for only particular locus and within specific cell populations or only one-cell population shows differences and some loci are divergent only in one cell subpopulation. This explains the concept of tumour heterogeneity and the order of genetic events during tumor evolution. Many of the genes driving the growth at primary site can determine the dissemination and colonization at the ectopic site.[3][4][5] Breast cancer is consensually considered genetically and clinically as a heterogeneous disease, in that it reflects the heterogeneity of the normal breast tissue at its origin17873350.[6] A number of discrete genetic events have to occur in order to enable individual tumor cells that have the capacity to grow at an ectopic site. The metastatic progression depends on the regulation of developmental programs and environmental events.[7] The metastatic potential of sub populations within mouse mammary cells is now considered as relatively an early event and dissemination occurs at the same time of pre invasive or micro-invasive lesions.[8][9] The genetic profiles of primary and metastatic lesions in breast carcinomas show a large extent of clonal pertinence between lesions.[10][11] There are various patterns of prevalence of genetic mutations in the genomes of primary breast tumour and its metastases.[12][13][14] It also confirms the genetic heterogeneity between the primary neoplasm of breast cancer patients and their respective metastases.[15][16]

Genes involved in organ specific metastasis

Breast cancer phenotypes periodically express genes in metastasis that are indispensable for the metastatic process. Metastatic diversity is mediated by the activation of genes that act as coupling to organ-specific growth.[17] The growth of lesions at the ectopic site depends on multiple complex interactions between metastatic cells and host homeostatic mechanisms. Lethal protein-protein interactions at the metastatic site aid the survival of adapted cells.[18]

Generating mouse models of breast cancer

Targeted expression of oncogenes in mouse mammary epithelial cells is a way of modeling human breast cancer. Mutation or over expression of oncogenes can be kept under controlled expression in a very specific cellular context rather than throughout the organism. Another way to model human breast cancer is done through the targeted inhibition of a tumor suppressor gene.[19]

Mice in genetic research

Human and mouse: a genomic comparison

Genetic studies of common diseases in humans suffer significant limitations for practical and ethical reasons.[22] Human cell lines can be used to model disease but it is difficult to study processes at the tissue level, within an organ or across the entire body. Mice can be a good representation of diseases in humans because:.[23]

Mice may not be an ideal model for breast cancer. This is mainly due to the lack of precision in many of the models. When looking at metastasis, it is difficult to determine the precise location as well as its frequency. Another issue revolves around the epithelial sub types and the inability to specifically target them when targeting a mutation. An example of this would be determining the development of tumors in K14-Cre BRCA2 mice. In a standard case, the excision of BRCA2 resulted in no tumorgenesis, but if p53 was mutated and inactivated, tumorgenesis would occur. Therefore, there is not a definitive answer in terms of the origin of the tumor, due to the extra mutation in p53.[24]

Metastatic mouse mammary carcinoma cell lines

Various mouse mammary carcinoma cell lines, like 4T1[25] and TS/A, are metastatic in syngeneic immunocompetent mice and can be used to identify genes and pathways involved in the metastatic process.[26]

Simple tumor transplantation models

Transplantation of tumor cells into immunodeficient mice is a tool to study breast cancer and its metastatic effects. The transplantation occurs as either allotransplants or xenographic transplants.[27] Commonly, human cells are inoculated in an immunocompromised murine recipient. Inoculating cells through intra ductal transplantations,[28] by cleared mammary fat pad injections[29][30] or by transplantations into the tail vein.[31][32][33] Different organs can be seeded with breast cancer cells depending on the route of injection[34]

Tumor tissue transplant models

The specific immunodeficient mice that were used were the NOD/SCID mouse (non-obese diabetic/severe conditional immunodeficient). These mutations allow for the integration of new xenograft tissue. The mouse must first have their mammary fat pads humanized by injecting human telemorase-immortalized human mammary stromal fibroblasts(RMF/EG fibroblasts) into the mammary fat pads. Without this injection, the human mammary epithelial cells en-grafted onto the pad are unable to colonize and grow. The RMF/EG fibroblast must then be irradiated to allow the expression of key proteins and growth factors. After 4 weeks of development, the newly en-grafted human mammary epithelial cells expanded within the fat pad.[35]

Genetically engineered mice to study metastasis

Genetically engineered mice are constructed to model human phenotypes and pathologies. Mutant mice may include transgenes using different delivery methods:

Transgenic mouse models of breast cancer

The mice undergoing the process of transgenesis are known as transgenic mice. A basic transgene has a promoter region, Protein coding sequence, Intron and a stop codon. Mouse mammary tumor virus (MMTV), is a retro virus that has been a known promoter to cause breast tumors once activated.[39] MMTV is a heritable somatic mutagen whose target range is limited. It harbors a regulatory DNA sequence called the long terminal repeat (LTR), which promotes steroid-hormone-inducible transcription.[40][41] Tumorgenesis that was induced by the mouse mammary tumor virus can also be done by integration of the viral genome. The sites of integration have been known to be critical genes for cellular regulation.[42] Whey acidic protein (WAP),[43] is another common promoter used to generate mouse mammary cancer models. For a list of other mammary gland specific promoters and mouse models see.[44]

Schematic representation of breast cancer metastatic study models

MMTV-PyMT

MMTV-PyMT is the model of breast cancer metastasis, in which MMTV-LTR is used to drive the expression of mammary gland specific polyomavirus middle T-antigen, leading to a rapid development of highly metastatic tumors.[45] MMTV-PyMT is the most commonly used model for the study of mammary tumor progression and metastasis. MMTV-PyMT mice are then crossed bred with other genetically modified mice to generate various types of breast cancer models, including:

MMTV-HER2/neu

The MMTV-LTR can also be used to promote receptor tyrosine-protein kinase ErbB2 to transform the mouse mammary epithelium. ErbB2 is an oncogene amplified and overexpressed in around 20% of human breast cancers. The mice harbouring this oncogene develop multifocal adenocarcinomas with lung metastases at about 15 weeks after pregnancy.[54][55] To create a more accurate representation of HER2 gene mutations, researchers have fused the mouse gene containing neu and a rat gene containing neu. This addresses the issue in terms of modeling the amplification of HER2 in mice development. In the non-fused mouse, the mammary gland would revert to a near virgin, but with this addition the mammary gland maintained the developed function.[56]

Bi-transgenic models

Mouse models having two transgenes are called bi transgenic. To check the cooperation of two oncogenes, Tim Stewert and group made the first bi-transgenic mouse models in 1987, MMTV-Myc and MMTV- Ras mice were crossed with a resulting acceleration in tumorigenesis.[57] Expression of TGFβ in the breast cancer cells of MMTV-ErbB2; MMTV-TGFβ double-transgenic mice can induce higher levels of circulating tumor cells and lung metastasis.[58] Ras gene can be combined with rtTA (reverse tetracycline transactivator) to generate bi-transgenic inducible mouse model through tetracycline-controlled transcriptional activation e.g. mice carrying TetO-KrasG12D (TOR) and MMTV-rtTA (MTB), comes with the transgene expressing the reverse tetracycline transactivator (rtTA) in mammary epithelial cells.[59]

Tri-transgenic models

Tri-transgenic mouse models constitute of more than two genes. Multiple combinations and genetic modifications are made in such a way that either one or all the genes are put into a continuously expressed status, or in a controlled fashion to activate them at different time points. For example, TOM( TetO-myc); TOR; MTB mice, where both the myc (M) and ras (R) genes are under the control of tetracycline operators. They can also both be activated or deactivated by adding doxycycline. Other combinations in this respect are TOM; Kras; MTB, where myc can be induced and uninduced at various time points while Kras is in continuous expressed state, and myc; TOR; MTB model is vice versa.[60]

Applications of genetically modified mice to study metastasis

Metastatic cascade can be studied by keeping the gene activation under control or by adding a reporter gene e.g. Beta actin GFP (Green fluorescent protein) or RFP (Red fluorescent protein).

Identification of genes that regulate metastasis

By knocking in/knocking out specific genes by homologous recombination, the extent of metastasis can be measured and new target genes identification can be achieved e.g. a gene that consistently regulates metastatic behavior of cancer cells is TGF-β1. Acute ablation of TGF-β signaling in MMTV-PyMT mammary tumor cells leads to a five-fold increase in lung metastasis.[61] Certain enhancer regions can also be analyzed and can be determined to be a crucial part of cell proliferation e.g. an enhancing region that is associated with a cancer critical gene p53 which was determined via CRISPR-Cas9.[62]

Lineage tracing in metastasis models

The quantitative lineage-tracing strategies have proven to be successful in resolving cell fates in normal epithelial tissues either using tissue –specific or stem-cell-specific transgenes. To conduct an inducible lineage-tracing experiment two components must be engineered into the mouse genome: a switch and a reporter. The switch is commonly a drug-regulated form of the bacterial enzyme Cre-recombinase. This enzyme recognizes specific sequences, called LoxP sites.[63] Proteins that are capable of enhancing the identification of labeled cells or a specific population in unlabelled cells are encoded by the reporter transgenes. After harvesting all the ten mouse mammary glands from the transgenic mice, single cell suspension is usually made and transplanted either in tail vein of non transgenic recipient mice[31] or in cleared fat pad of non-transgenic mice repopulating the mammary fat pad.[64] These cells are then followed in the blood stream, lungs, bone marrow and liver to look for the favorable site of metastasis.these transgenic cells can be traced according to their special features of either fluorescence or induced by placing the recipients on doxycycline food.[citation needed]

Circulating tumor cells

Another tool to study breast cancer metastasis is to look for circulating tumor cells in transgenic mice e.g. MMTV-PyMT mice can respond to various therapies in shedding tumor cells in the blood leading to lung metastasis.[65] Not only in blood but cells can be detected in bone marrow e.g. cytokeratin-positive cells in the bone marrow of MMTV-pyMT and MMTV-Neu transgenic mice were identified but not in the wild type controls.[66]

Limitations

In the absence of specific markers for mammary cells, models with genetic marking of tumor cells gives the best experimental advantage, however the low volume of peripheral blood that can be obtained from live animals limits the application of this technique.

In vivo imaging of metastatic mouse models

Transgenic mouse models can be imaged by various non-invasive techniques.

Bio luminescence Imaging

Bioluminescence imaging

Bioluminescence imaging relies on the detection of light produced by the enzymatic oxidation of an exogenous substrate. The substrate luciferin, is oxidized to oxyluciferin in the presence of luciferase and emits light, which can be detected using an IVIS system such as a Xenogen machine. Dissociated mammary cells from MMTV-PyMT: IRES: Luc; MTB (Internal ribosome entry site: Luciferin) animals (which were not exposed to doxycycline) can be injected into the lateral tail veins of immunodeficient mice on a doxycycline-free diet. No bioluminescence signal will be observed in the lungs of recipient mice until they are given doxycycline food. Bioluminescence can then be detected in the chest within 2 weeks of the start of doxycycline exposure.[31] Luciferase is injected just before taking the images.

Fluorescent imaging

Intravital microscopy with multi photon excitation is a technique to visualize genetically engineered cells directly in vivo. Multi step metastatic cascades can be visualized by labelling with unique fluorescent colour under fluorescence microscope.[67][68]

Radioisotopic imaging

Positron emission tomography (PET), single photon emission computed tomography (SPECT) and computed tomography (CT) have been used to compare the efficiency of these in vivo imaging for detecting lesions at an early stage and to evaluate the response to chemotherapy.[69]

MRI Imaging

Magnetic resonance imaging requires the use of nano-particles(liposomes) and an MRI contrast agent called gadolinium. The particles were then placed in vesicles via a polycarbonate membrane filter. The nano-particles are injected into the metastases evolved mice, and left there for twenty-four hours. These mice are then scanned, and in the imaging software there are accumulations of these particles in certain areas where cells have metastasized.[22]

See also

References

  1. ^ Hanahan, D.; Weinberg, R. (2000). "The hallmarks of cancer". Cell. 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9. PMID 10647931.
  2. ^ Fidler, I. J. (1973). "Selection of successive tumour lines for metastasis". Nature New Biology. 242 (118): 148–9. doi:10.1038/newbio242148a0. PMID 4512654.
  3. ^ Martins, F. C.; De, S; Almendro, V; Gönen, M; Park, S. Y.; Blum, J. L.; Herlihy, W; Ethington, G; Schnitt, S. J.; Tung, N; Garber, J. E.; Fetten, K; Michor, F; Polyak, K (2012). "Evolutionary pathways in BRCA1-associated breast tumors". Cancer Discovery. 2 (6): 503–11. doi:10.1158/2159-8290.CD-11-0325. PMC 3738298. PMID 22628410.
  4. ^ Shah, S. P.; Morin, R. D.; Khattra, J; Prentice, L; Pugh, T; Burleigh, A; Delaney, A; Gelmon, K; Guliany, R; Senz, J; Steidl, C; Holt, R. A.; Jones, S; Sun, M; Leung, G; Moore, R; Severson, T; Taylor, G. A.; Teschendorff, A. E.; Tse, K; Turashvili, G; Varhol, R; Warren, R. L.; Watson, P; Zhao, Y; Caldas, C; Huntsman, D; Hirst, M; Marra, M. A.; Aparicio, S (2009). "Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution". Nature. 461 (7265): 809–13. Bibcode:2009Natur.461..809S. doi:10.1038/nature08489. PMID 19812674.
  5. ^ Geyer, F. C.; Weigelt, B; Natrajan, R; Lambros, M. B.; De Biase, D; Vatcheva, R; Savage, K; MacKay, A; Ashworth, A; Reis-Filho, J. S. (2010). "Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas". The Journal of Pathology. 220 (5): 562–73. doi:10.1002/path.2675. PMID 20099298.
  6. ^ Ashkenazi, R; Jackson, T. L.; Dontu, G; Wicha, M. S. (2007). "Breast cancer stem cells-research opportunities utilizing mathematical modeling". Stem Cell Reviews. 3 (2): 176–82. doi:10.1007/s12015-007-0026-2. PMID 17873350. S2CID 22296676.
  7. ^ Müller, A; Homey, B; Soto, H; Ge, N; Catron, D; Buchanan, M. E.; McClanahan, T; Murphy, E; Yuan, W; Wagner, S. N.; Barrera, J. L.; Mohar, A; Verástegui, E; Zlotnik, A (2001). "Involvement of chemokine receptors in breast cancer metastasis". Nature. 410 (6824): 50–6. Bibcode:2001Natur.410...50M. doi:10.1038/35065016. PMID 11242036. S2CID 4321110.
  8. ^ Klein, C. A. (2009). "Parallel progression of primary tumours and metastases". Nature Reviews Cancer. 9 (4): 302–12. doi:10.1038/nrc2627. PMID 19308069. S2CID 9161392.
  9. ^ Weng, D; Penzner, J. H.; Song, B; Koido, S; Calderwood, S. K.; Gong, J (2012). "Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers". Breast Cancer Research. 14 (1): R18. doi:10.1186/bcr3102. PMC 3496135. PMID 22277639.
  10. ^ Liu, W; Laitinen, S; Khan, S; Vihinen, M; Kowalski, J; Yu, G; Chen, L; Ewing, C. M.; Eisenberger, M. A.; Carducci, M. A.; Nelson, W. G.; Yegnasubramanian, S; Luo, J; Wang, Y; Xu, J; Isaacs, W. B.; Visakorpi, T; Bova, G. S. (2009). "Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer". Nature Medicine. 15 (5): 559–65. doi:10.1038/nm.1944. PMC 2839160. PMID 19363497.
  11. ^ Torres, L; Ribeiro, F. R.; Pandis, N; Andersen, J. A.; Heim, S; Teixeira, M. R. (2007). "Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases". Breast Cancer Research and Treatment. 102 (2): 143–55. doi:10.1007/s10549-006-9317-6. PMID 16906480. S2CID 33824409.
  12. ^ Pandis, N; Teixeira, M. R.; Adeyinka, A; Rizou, H; Bardi, G; Mertens, F; Andersen, J. A.; Bondeson, L; Sfikas, K; Qvist, H; Apostolikas, N; Mitelman, F; Heim, S (1998). "Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients". Genes, Chromosomes and Cancer. 22 (2): 122–9. doi:10.1002/(SICI)1098-2264(199806)22:2<122::AID-GCC6>3.0.CO;2-Z. PMID 9598799. S2CID 22599771.
  13. ^ Kuukasjärvi, T; Karhu, R; Tanner, M; Kähkönen, M; Schäffer, A; Nupponen, N; Pennanen, S; Kallioniemi, A; Kallioniemi, O. P.; Isola, J (1997). "Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer". Cancer Research. 57 (8): 1597–604. PMID 9108466.
  14. ^ Bonsing, B. A.; Corver, W. E.; Fleuren, G. J.; Cleton-Jansen, A. M.; Devilee, P; Cornelisse, C. J. (2000). "Allelotype analysis of flow-sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases". Genes, Chromosomes and Cancer. 28 (2): 173–83. doi:10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO;2-1. PMID 10825002. S2CID 36147250.
  15. ^ Wu, J. M.; Fackler, M. J.; Halushka, M. K.; Molavi, D. W.; Taylor, M. E.; Teo, W. W.; Griffin, C; Fetting, J; Davidson, N. E.; De Marzo, A. M.; Hicks, J. L.; Chitale, D; Ladanyi, M; Sukumar, S; Argani, P (2008). "Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases". Clinical Cancer Research. 14 (7): 1938–46. doi:10.1158/1078-0432.CCR-07-4082. PMC 2965068. PMID 18381931.
  16. ^ Schmidt-Kittler, O; Ragg, T; Daskalakis, A; Granzow, M; Ahr, A; Blankenstein, T. J.; Kaufmann, M; Diebold, J; Arnholdt, H; Muller, P; Bischoff, J; Harich, D; Schlimok, G; Riethmuller, G; Eils, R; Klein, C. A. (2003). "From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression". Proceedings of the National Academy of Sciences. 100 (13): 7737–42. Bibcode:2003PNAS..100.7737S. doi:10.1073/pnas.1331931100. PMC 164657. PMID 12808139.
  17. ^ Martín, B; Sanz, R; Aragüés, R; Oliva, B; Sierra, A (2008). "Functional clustering of metastasis proteins describes plastic adaptation resources of breast-cancer cells to new microenvironments". Journal of Proteome Research. 7 (8): 3242–53. doi:10.1021/pr800137w. PMID 18582095.
  18. ^ Langley, R. R.; Fidler, I. J. (2007). "Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis". Endocrine Reviews. 28 (3): 297–321. doi:10.1210/er.2006-0027. PMID 17409287.
  19. ^ Gupta, PB; Kuperwasser, C. (2004). Disease models of breast cancer. Drug Discovery Today: Disease Models 1(1), 9-16. doi: 10.1016/j.ddmod.2004.05.001
  20. ^ Palmiter, R. D.; Brinster, R. L.; Hammer, R. E.; Trumbauer, M. E.; Rosenfeld, M. G.; Birnberg, N. C.; Evans, R. M. (1992). "Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. 1982". Biotechnology (Reading, Mass.). 24: 429–33. PMID 1422050.
  21. ^ Nusse, R; Varmus, H. E. (1982). "Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome". Cell. 31 (1): 99–109. doi:10.1016/0092-8674(82)90409-3. PMID 6297757. S2CID 46024617.
  22. ^ a b Goldman, E; Zinger, A; Silva, DD; Yaari, Z; Vardi-Oknin, D; Goldfeder, M; Schroeder, JE; Shainsky-Roitman, J; Hershkovitz, D; Schroeder, A; (2017). Nanoparticles target early-stage breast cancer metastasis in vivo. Nanotechnology 28(43), 1-13. doi: 10.1086/13616528/aa8a3d
  23. ^ Chinwalla, A. T.; Waterston, L. L.; Lindblad-Toh, K. D.; Birney, G. A.; Rogers, L. A.; Abril, R. S.; Agarwal, T. A.; Agarwala, L. W.; Ainscough, E. R.; Alexandersson, J. D.; An, T. L.; Antonarakis, W. E.; Attwood, J. O.; Baertsch, M. N.; Bailey, K. H.; Barlow, C. S.; Beck, T. C.; Berry, B.; Birren, J.; Bloom, E.; Bork, R. H.; Botcherby, M. C.; Bray, R. K.; Brent, S. P.; Brown, P.; Brown, E.; Bult, B.; Burton, T.; Butler, D. G.; et al. (2002). "Initial sequencing and comparative analysis of the mouse genome". Nature. 420 (6915): 520–562. Bibcode:2002Natur.420..520W. doi:10.1038/nature01262. PMID 12466850.
  24. ^ Wagner, KW. (2003). Models of Breast Cancer: quo vadis, animal modeling? Breast Cancer Research 6(31), 31-38.doi: 10.1186/bcr723
  25. ^ Pulaski BA, S Ostrand-Rosenberg. 2001. "Mouse 4T1 breast tumor model". Curr Protoc Immunol. Chapter 20:Unit 20.2. doi: 10.1002/0471142735.im2002s39
  26. ^ Knott SRV, E Wagenblast, S Khan, SY Kim, M Soto, M Wagner, M-O Turgeon, L Fish, N Erard, AL Gable, AR Maceli, S Dickopf, EK Papachristou, CS D’Santos, LA Carey, JE Wilkinson, JC Harrell, CM Perou, H Goodarzi, G Poulogiannis, and GJ Hannon. 2018. "Asparagine bioavailability governs metastasis in a model of breast cancer". Nature. doi:10.1038/nature25465
  27. ^ Khanna, C; Hunter, K (2005). "Modeling metastasis in vivo". Carcinogenesis. 26 (3): 513–23. doi:10.1093/carcin/bgh261. PMID 15358632.
  28. ^ Behbod, F; Kittrell, F. S.; Lamarca, H; Edwards, D; Kerbawy, S; Heestand, J. C.; Young, E; Mukhopadhyay, P; Yeh, H. W.; Allred, D. C.; Hu, M; Polyak, K; Rosen, J. M.; Medina, D (2009). "An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ". Breast Cancer Research. 11 (5): R66. doi:10.1186/bcr2358. PMC 2790841. PMID 19735549.
  29. ^ Aslakson, C. J.; Miller, F. R. (1992). "Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor". Cancer Research. 52 (6): 1399–405. PMID 1540948.
  30. ^ Yang, Jing; Mani, Sendurai A; Donaher, Joana Liu; Ramaswamy, Sridhar; Itzykson, Raphael A; Come, Christophe; Savagner, Pierre; Gitelman, Inna; Richardson, Andrea; Weinberg, Robert A (2004). "Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis". Cell. 117 (7): 927–39. doi:10.1016/j.cell.2004.06.006. PMID 15210113.
  31. ^ a b c Podsypanina, K; Du, Y. C.; Jechlinger, M; Beverly, L. J.; Hambardzumyan, D; Varmus, H (2008). "Seeding and propagation of untransformed mouse mammary cells in the lung". Science. 321 (5897): 1841–4. Bibcode:2008Sci...321.1841P. doi:10.1126/science.1161621. PMC 2694414. PMID 18755941.
  32. ^ Talmadge, J. E.; Singh, R. K.; Fidler, I. J.; Raz, A (2007). "Murine models to evaluate novel and conventional therapeutic strategies for cancer". The American Journal of Pathology. 170 (3): 793–804. doi:10.2353/ajpath.2007.060929. PMC 1864878. PMID 17322365.
  33. ^ Kim, M. Y.; Oskarsson, T; Acharyya, S; Nguyen, D. X.; Zhang, X. H.; Norton, L; Massagué, J (2009). "Tumor self-seeding by circulating cancer cells". Cell. 139 (7): 1315–26. doi:10.1016/j.cell.2009.11.025. PMC 2810531. PMID 20064377.
  34. ^ Vargo-Gogola, T; Rosen, J. M. (2007). "Modelling breast cancer: One size does not fit all". Nature Reviews Cancer. 7 (9): 659–72. doi:10.1038/nrc2193. PMID 17721431. S2CID 44649920.
  35. ^ Kuperwasser, C; Chavarria, T; Wu, M; Magrane, G; Gray, JW; Carey, L; Richardson, A; Weinberg, RA. (2004). Reconstruction of functionally normal and malignant human breast tissue in mice. Pnas 101(14), 4966-4971. doi: 10.1073/pnas.0401064101
  36. ^ Gossen, M; Bujard, H (1992). "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters". Proceedings of the National Academy of Sciences of the United States of America. 89 (12): 5547–51. Bibcode:1992PNAS...89.5547G. doi:10.1073/pnas.89.12.5547. PMC 49329. PMID 1319065.
  37. ^ Sauer, B; Henderson, N (1989). "Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome". Nucleic Acids Research. 17 (1): 147–61. doi:10.1093/nar/17.1.147. PMC 331541. PMID 2783482.
  38. ^ Du, Z; Podsypanina, K; Huang, S; McGrath, A; Toneff, M. J.; Bogoslovskaia, E; Zhang, X; Moraes, R. C.; Fluck, M; Allred, D. C.; Lewis, M. T.; Varmus, H. E.; Li, Y (2006). "Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models". Proceedings of the National Academy of Sciences. 103 (46): 17396–401. Bibcode:2006PNAS..10317396D. doi:10.1073/pnas.0608607103. PMC 1635021. PMID 17090666.
  39. ^ Callahan, R; Smith, G. H. (2000). "MMTV-induced mammary tumorigenesis: Gene discovery, progression to malignancy and cellular pathways". Oncogene. 19 (8): 992–1001. doi:10.1038/sj.onc.1203276. PMID 10713682.
  40. ^ Ringold, G. M.; Yamamoto, K. R.; Tomkins, G. M.; Bishop, M; Varmus, H. E. (1975). "Dexamethasone-mediated induction of mouse mammary tumor virus RNA: A system for studying glucocorticoid action". Cell. 6 (3): 299–305. doi:10.1016/0092-8674(75)90181-6. PMID 212202. S2CID 20773799.
  41. ^ Yamamoto, K. R.; Payvar, F; Firestone, G. L.; Maler, B. A.; Wrange, O; Carlstedt-Duke, J; Gustafsson, J. A.; Chandler, V. L. (1983). "Biological activity of cloned mammary tumor virus DNA fragments that bind purified glucocorticoid receptor protein in vitro". Cold Spring Harbor Symposia on Quantitative Biology. 47 (2): 977–84. doi:10.1101/sqb.1983.047.01.111. PMID 6305596.
  42. ^ Ross, RS. (2010). Mouse mammary tumor virus molecular biology and oncogenesis. Viruses 2(9), 2000-2012. doi: 10.3390/v2092000
  43. ^ Campbell, S. M.; Rosen, J. M.; Hennighausen, L. G.; Strech-Jurk, U; Sippel, A. E. (1984). "Comparison of the whey acidic protein genes of the rat and mouse". Nucleic Acids Research. 12 (22): 8685–97. doi:10.1093/nar/12.22.8685. PMC 320407. PMID 6095207.
  44. ^ Fantozzi, A; Christofori, G (2006). "Mouse models of breast cancer metastasis". Breast Cancer Research. 8 (4): 212. doi:10.1186/bcr1530. PMC 1779475. PMID 16887003.
  45. ^ Guy, C. T.; Cardiff, R. D.; Muller, W. J. (1992). "Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease". Molecular and Cellular Biology. 12 (3): 954–61. doi:10.1128/mcb.12.3.954. PMC 369527. PMID 1312220.
  46. ^ Klarenbeek, S; Van Miltenburg, M. H.; Jonkers, J (2013). "Genetically engineered mouse models of PI3K signaling in breast cancer". Molecular Oncology. 7 (2): 146–64. doi:10.1016/j.molonc.2013.02.003. PMC 5528412. PMID 23478237.
  47. ^ Lin, E. Y.; Nguyen, A. V.; Russell, R. G.; Pollard, J. W. (2001). "Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy". The Journal of Experimental Medicine. 193 (6): 727–40. doi:10.1084/jem.193.6.727. PMC 2193412. PMID 11257139.
  48. ^ Denardo, D. G.; Barreto, J. B.; Andreu, P; Vasquez, L; Tawfik, D; Kolhatkar, N; Coussens, L. M. (2009). "CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages". Cancer Cell. 16 (2): 91–102. doi:10.1016/j.ccr.2009.06.018. PMC 2778576. PMID 19647220.
  49. ^ Lopez, J. I.; Camenisch, T. D.; Stevens, M. V.; Sands, B. J.; McDonald, J; Schroeder, J. A. (2005). "CD44 attenuates metastatic invasion during breast cancer progression". Cancer Research. 65 (15): 6755–63. doi:10.1158/0008-5472.CAN-05-0863. PMID 16061657.
  50. ^ Schoeffner, D. J.; Matheny, S. L.; Akahane, T; Factor, V; Berry, A; Merlino, G; Thorgeirsson, U. P. (2005). "VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms". Laboratory Investigation. 85 (5): 608–23. doi:10.1038/labinvest.3700258. PMID 15765121.
  51. ^ Muraoka-Cook, R. S.; Kurokawa, H; Koh, Y; Forbes, J. T.; Roebuck, L. R.; Barcellos-Hoff, M. H.; Moody, S. E.; Chodosh, L. A.; Arteaga, C. L. (2004). "Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors". Cancer Research. 64 (24): 9002–11. doi:10.1158/0008-5472.CAN-04-2111. PMID 15604265.
  52. ^ Almholt, K; Lund, L. R.; Rygaard, J; Nielsen, B. S.; Danø, K; Rømer, J; Johnsen, M (2005). "Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice". International Journal of Cancer. 113 (4): 525–32. doi:10.1002/ijc.20631. PMID 15472905.
  53. ^ Cuevas, B. D.; Winter-Vann, A. M.; Johnson, N. L.; Johnson, G. L. (2006). "MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer". Oncogene. 25 (36): 4998–5010. doi:10.1038/sj.onc.1209507. PMID 16568086.
  54. ^ Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A; McGuire, W. L. (1987). "Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene". Science. 235 (4785): 177–82. Bibcode:1987Sci...235..177S. doi:10.1126/science.3798106. PMID 3798106.
  55. ^ Muller, W. J.; Sinn, E; Pattengale, P. K.; Wallace, R; Leder, P (1988). "Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene". Cell. 54 (1): 105–15. doi:10.1016/0092-8674(88)90184-5. PMID 2898299. S2CID 33754359.
  56. ^ Fry, EA; Taneka, P; Inoue, K. (2016). Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu. International Journal of Cancer 140(3), 495-503. doi:10.1002/ijc.30399
  57. ^ Sinn, E; Muller, W; Pattengale, P; Tepler, I; Wallace, R; Leder, P (1987). "Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo". Cell. 49 (4): 465–75. doi:10.1016/0092-8674(87)90449-1. PMID 3032456. S2CID 43820016.
  58. ^ Siegel, P. M.; Shu, W; Cardiff, R. D.; Muller, W. J.; Massagué, J (2003). "Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis". Proceedings of the National Academy of Sciences. 100 (14): 8430–5. Bibcode:2003PNAS..100.8430S. doi:10.1073/pnas.0932636100. PMC 166246. PMID 12808151.
  59. ^ Gunther, E. J.; Belka, G. K.; Wertheim, G. B.; Wang, J; Hartman, J. L.; Boxer, R. B.; Chodosh, L. A. (2002). "A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology". The FASEB Journal. 16 (3): 283–92. doi:10.1096/fj.01-0551com. PMID 11874978. S2CID 34303003.
  60. ^ Podsypanina, K; Politi, K; Beverly, L. J.; Varmus, H. E. (2008). "Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras". Proceedings of the National Academy of Sciences. 105 (13): 5242–7. Bibcode:2008PNAS..105.5242P. doi:10.1073/pnas.0801197105. PMC 2278195. PMID 18356293.
  61. ^ Bierie, B; Stover, D. G.; Abel, T. W.; Chytil, A; Gorska, A. E.; Aakre, M; Forrester, E; Yang, L; Wagner, K. U.; Moses, H. L. (2008). "Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment". Cancer Research. 68 (6): 1809–19. doi:10.1158/0008-5472.CAN-07-5597. PMID 18339861.
  62. ^ Korkmaz, G; Lopes, R; Ugalde, AP; Nevedomskaya, E; Han, R; Myacheva, K; Zwart, W; Elkon, R; Agami, R. (2016). Functional genetics screens for enhancer elements in the human genome using CRISPR-Cas9. Nature Biotechnology 34, 192-198. doi: 10.1038/nbt.3450
  63. ^ Srinivas, S; Watanabe, T; Lin, C. S.; William, C. M.; Tanabe, Y; Jessell, T. M.; Costantini, F (2001). "Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus". BMC Developmental Biology. 1: 4. doi:10.1186/1471-213X-1-4. PMC 31338. PMID 11299042.
  64. ^ Liao, M. J.; Zhang, C. C.; Zhou, B; Zimonjic, D. B.; Mani, S. A.; Kaba, M; Gifford, A; Reinhardt, F; Popescu, N. C.; Guo, W; Eaton, E. N.; Lodish, H. F.; Weinberg, R. A. (2007). "Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity". Cancer Research. 67 (17): 8131–8. doi:10.1158/0008-5472.CAN-06-4493. PMID 17804725.
  65. ^ Biswas, S; Guix, M; Rinehart, C; Dugger, T. C.; Chytil, A; Moses, H. L.; Freeman, M. L.; Arteaga, C. L. (2007). "Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression". Journal of Clinical Investigation. 117 (5): 1305–13. doi:10.1172/JCI30740. PMC 1838926. PMID 17415413.
  66. ^ Hüsemann, Y; Geigl, J. B.; Schubert, F; Musiani, P; Meyer, M; Burghart, E; Forni, G; Eils, R; Fehm, T; Riethmüller, G; Klein, C. A. (2008). "Systemic spread is an early step in breast cancer". Cancer Cell. 13 (1): 58–68. doi:10.1016/j.ccr.2007.12.003. PMID 18167340.
  67. ^ Egeblad, M; Nakasone, E. S.; Werb, Z (2010). "Tumors as organs: Complex tissues that interface with the entire organism". Developmental Cell. 18 (6): 884–901. doi:10.1016/j.devcel.2010.05.012. PMC 2905377. PMID 20627072.
  68. ^ Entenberg, D; Wyckoff, J; Gligorijevic, B; Roussos, E. T.; Verkhusha, V. V.; Pollard, J. W.; Condeelis, J (2011). "Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging". Nature Protocols. 6 (10): 1500–20. doi:10.1038/nprot.2011.376. PMC 4028841. PMID 21959234.
  69. ^ Alberini, Jean-Louis; Boisgard, Raphaël; Guillermet, Stéphanie; Siquier, Karine; Jego, Benoît; Thézé, Benoît; Urien, Saik; Rezaï, Keyvan; Menet, Emmanuelle (2016-08-01). "Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer". Molecular Imaging and Biology. 18 (4): 617–626. doi:10.1007/s11307-015-0916-7. ISSN 1860-2002. PMC 4927598. PMID 26630973.

External links

Categories